This website is intended for healthcare professionals only

touchNEUROLOGY

Search

Trending Topic

Developed by Touch

European Stroke Organisation Conference 2026: Expanding the boundaries of acute stroke care

Federica Rizzo, Ettore Nicolini, Antonio Ciacciarelli

The 12th European Stroke Organisation Conference (Maastricht, May 6–8, 2026) was dominated by studies testing the limits of acute stroke therapy, from thrombectomy and neuroprotection to secondary prevention. Supplementary Table 1 provides a comprehensive overview of the major studies presented during the conference. The large-core indication for thrombectomy is recent, and the ATLAS (Endovascular thrombectomy […]

touchREVIEWS in Neurology. 2026;22(1):Online ahead of journal publication

Headache Disorders

EAN 2016 Peter Goadsby Interview

Published Online: Jun 24th 2016

Peter Goadsby discusses the rationale for using CGRP antibodies in the treatment of migraine and the study findings so far.

Trending Topic

Developed by Touch

Headache disorders at EAN24: Developments and the future

Peter J Goadsby

Data from the REFORM trial (NCT04674020) provide valuable insights into cortical inflammation in adults with migraines, using a novel quantitative, multimodal MRI technique to compare these patients with age- and gender-matched healthy controls, enhancing our understanding of migraine biology and other headache disorders. The discussion also covers cluster headaches, focusing on a study that examines premonitory symptoms in affected individuals and highlights key phenotypic characteristics. Additionally, we explore findings from the European Migraine & Headache Alliance on the stigma surrounding migraines, which yield insightful and actionable results. Looking ahead, the focus shifts to the latest data on new medications for preventing and treating migraine attacks, discussing future prospects and identifying areas in headache disorder management that still need further attention.

Related Videos in Headache Disorders

Developed by Touch

Peter Goadsby, EAN 2023: Highlights in migraine

In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King's college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a ...

Developed by Touch

Peter Goadsby, EAN 2023: Highlights in headache disorders

In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King's college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in ...

Developed by Touch

Highlights from EAN 2023!

...

Developed by Touch

Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial

Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very ...

Developed by Touch

Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023

Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with ...

Developed by Touch

Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine

Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data ...

Developed by Touch

Stewart Tepper, AAN 2023: Significant reduction in migraine days with REN for migraine prevention: A double-blind randomized sham-controlled clinical trial

Migraine affects over 1 billion people worldwide causing significant disability and a socioeconomic burden. Preventive treatment is key to managing migraine, but it is often underutilized. Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes his presentation ...

Developed by Touch

Stewart Tepper, AAN 2023: Phase 3 ASCEND interim analysis - STS101 for the treatment of acute migraine

Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes safety and tolerability data from the ASCEND study of STS101 5.2 mg (dihydroergotamine nasal powder) in the acute treatment of migraine attacks with/without aura over 12 months. STS101 ...

Developed by Touch

Stewart Tepper, AAN 2023: Combination of rizatriptan and AXS-07 - results from the MOMENTUM and INTERCEPT studies

A better understanding of the key areas of unmet need regarding acute migraine therapy may help inform drug development and treatment selection. Prof Stewart Tepper (Geisal School of Medicine - Dartmouth, Hanover, NH, USA) summarizes a poster on data from ...

Developed by Touch

Robert Music, The Migraine Trust: Improving migraine care - ensuring patient-focussed diagnosis and treatment in the UK

"Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges ...

Developed by Touch

Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine - Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19

Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted ...

Stewart Tepper

Developed by Touch

Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine

The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new ...

Latest articles videos and clinical updates - straight to your inbox

Sign Up

Login

Sign Up FREE

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Sign up with an Email

Sign up with Google

Sign up with Facebook

Sign up with LinkedIn

Sign up with Microsoft

Already have an Account?

Login

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Register

Login